CN101490022A - 作为5-羟色胺-6配体的苯并唑和苯并噻唑衍生物 - Google Patents

作为5-羟色胺-6配体的苯并唑和苯并噻唑衍生物 Download PDF

Info

Publication number
CN101490022A
CN101490022A CNA2007800261442A CN200780026144A CN101490022A CN 101490022 A CN101490022 A CN 101490022A CN A2007800261442 A CNA2007800261442 A CN A2007800261442A CN 200780026144 A CN200780026144 A CN 200780026144A CN 101490022 A CN101490022 A CN 101490022A
Authority
CN
China
Prior art keywords
benzoxazole
piperazin
naphthylsulfonyl
compound
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800261442A
Other languages
English (en)
Chinese (zh)
Inventor
凯文·刘
艾伯特·琼·罗比肖
哈森·马哈茂德·埃洛克达赫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of CN101490022A publication Critical patent/CN101490022A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNA2007800261442A 2006-06-01 2007-05-25 作为5-羟色胺-6配体的苯并唑和苯并噻唑衍生物 Pending CN101490022A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80999606P 2006-06-01 2006-06-01
US60/809,996 2006-06-01

Publications (1)

Publication Number Publication Date
CN101490022A true CN101490022A (zh) 2009-07-22

Family

ID=38668755

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800261442A Pending CN101490022A (zh) 2006-06-01 2007-05-25 作为5-羟色胺-6配体的苯并唑和苯并噻唑衍生物

Country Status (17)

Country Link
US (1) US7501421B2 (cg-RX-API-DMAC7.html)
EP (1) EP2024348A2 (cg-RX-API-DMAC7.html)
JP (1) JP2009538909A (cg-RX-API-DMAC7.html)
KR (1) KR20090023641A (cg-RX-API-DMAC7.html)
CN (1) CN101490022A (cg-RX-API-DMAC7.html)
AR (1) AR061147A1 (cg-RX-API-DMAC7.html)
AU (1) AU2007255041A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0712444A2 (cg-RX-API-DMAC7.html)
CA (1) CA2659701A1 (cg-RX-API-DMAC7.html)
CR (1) CR10474A (cg-RX-API-DMAC7.html)
EC (1) ECSP088930A (cg-RX-API-DMAC7.html)
IL (1) IL195590A0 (cg-RX-API-DMAC7.html)
MX (1) MX2008015328A (cg-RX-API-DMAC7.html)
NO (1) NO20085045L (cg-RX-API-DMAC7.html)
PE (1) PE20080707A1 (cg-RX-API-DMAC7.html)
TW (1) TW200804310A (cg-RX-API-DMAC7.html)
WO (1) WO2007142904A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105431427A (zh) * 2013-07-10 2016-03-23 明治制果药业株式会社 新型pde4 抑制剂

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG174125A1 (en) * 2009-04-02 2011-10-28 Merck Serono Sa Dihydroorotate dehydrogenase inhibitors
KR101250606B1 (ko) * 2011-01-24 2013-04-03 이화여자대학교 산학협력단 5-ht6 수용체 억제 작용을 갖는 신규한 벤조티아졸 및 벤즈이소티아졸유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
AU2015286049B2 (en) 2014-07-08 2018-03-01 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7582635B2 (en) 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
GB0422263D0 (en) * 2004-10-07 2004-11-10 Glaxo Group Ltd Novel compounds

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105431427A (zh) * 2013-07-10 2016-03-23 明治制果药业株式会社 新型pde4 抑制剂
CN105431427B (zh) * 2013-07-10 2017-12-08 明治制果药业株式会社 新型pde4 抑制剂
US9890142B2 (en) 2013-07-10 2018-02-13 Meiji Seika Pharma Co., Ltd. PDE4 inhibitor

Also Published As

Publication number Publication date
CR10474A (es) 2009-01-07
US7501421B2 (en) 2009-03-10
AR061147A1 (es) 2008-08-06
TW200804310A (en) 2008-01-16
JP2009538909A (ja) 2009-11-12
ECSP088930A (es) 2009-01-30
NO20085045L (no) 2008-12-12
BRPI0712444A2 (pt) 2012-06-05
PE20080707A1 (es) 2008-05-22
WO2007142904A2 (en) 2007-12-13
CA2659701A1 (en) 2007-12-13
KR20090023641A (ko) 2009-03-05
WO2007142904A3 (en) 2008-02-07
US20070281945A1 (en) 2007-12-06
EP2024348A2 (en) 2009-02-18
AU2007255041A1 (en) 2007-12-13
MX2008015328A (es) 2008-12-12
IL195590A0 (en) 2009-09-01

Similar Documents

Publication Publication Date Title
US20070281922A1 (en) 1-Sulfonylindazolylamine and - amide derivatives as 5-hydroxytryptamine-6 ligands
JP2006517966A (ja) 5−ヒドロキシトリプタミン−6リガンドとしてのヘテロサイクリル−3−スルホニルアザインドールまたは−アザインダゾール誘導体
JP2006528186A (ja) 5−ヒドロキシトリプタミン−6リガンドとしてのスルホニルジヒドロベンゾイミダゾロン化合物
US7288561B2 (en) Sulfonyltetrahydro-3H-benzo(E)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands
US7414051B2 (en) Substituted-dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands
US7501421B2 (en) Benzoxazole and benzothiazole derivatives as 5-hydroxytryptamine-6 ligands
EP0806419A1 (en) Benzoxazole derivatives as serotonin 5-HT3 receptor partial activator
US20070244179A1 (en) Dihydro[1,4]dioxino[2,3-e]indazole derivatives as 5-hydroxytryptamine-6 ligands
US7482461B2 (en) Sulfonyl-3-heterocyclylindazole derivatives as 5-hydroxytryptamine-6 ligands
CA2619309A1 (en) Azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands
US7429582B2 (en) Dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands and use thereof in the treatment of attention deficit disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090722